Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00035633 · ClinicalTrials.gov registry record · Phase 3
A Phase III Study of Entecavir vs Lamivudine in Adults With Chronic Hepatitis B Infection and Positive for Hepatitis B E Antigen
A Phase 3 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 3
- Development phase
NCT00035633 is a Phase 3 study that has completed, run by Bristol-Myers Squibb.
The verdict
NCT00035633, a Phase 3 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 3
- Development phase
Study Summary
The purpose of this clinical research study is to assess the safety effectiveness of entecavir, as compared to lamivudine, in the treatment of adults with chronic hepatitis B infection who are hepatitis B e antigen positive.
Interventions
- DRUG Entecavir
Trial Details
| Field | Value |
|---|---|
| Start Date | 2001-12 |
| Est. Completion | 2005-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00035633
The ClinicalTrials.gov registry entry for NCT00035633 describes a study currently listed as completed, categorized as Phase 3. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Entecavir is the first listed.
NCT00035633 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00035633 about?
NCT00035633 is a clinical study titled "A Phase III Study of Entecavir vs Lamivudine in Adults With Chronic Hepatitis B Infection and Positive for Hepatitis B E Antigen". The purpose of this clinical research study is to assess the safety effectiveness of entecavir, as compared to lamivudine, in the treatment of adults with chronic hepatitis B infection who are hepatitis B e antigen positive.
What is the current status of trial NCT00035633?
This trial is currently completed. It is a Phase 3 study. The study started on 2001-12. Estimated completion is 2005-02.
What interventions are being tested in trial NCT00035633?
The interventions under investigation include: Entecavir (DRUG).
Who is sponsoring clinical trial NCT00035633?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.